Back to Search Start Over

YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias

Authors :
Franc Llorens
Katrin Thüne
Waqas Tahir
Eirini Kanata
Daniela Diaz-Lucena
Konstantinos Xanthopoulos
Eleni Kovatsi
Catharina Pleschka
Paula Garcia-Esparcia
Matthias Schmitz
Duru Ozbay
Susana Correia
Ângela Correia
Ira Milosevic
Olivier Andréoletti
Natalia Fernández-Borges
Ina M. Vorberg
Markus Glatzel
Theodoros Sklaviadis
Juan Maria Torres
Susanne Krasemann
Raquel Sánchez-Valle
Isidro Ferrer
Inga Zerr
Source :
Molecular Neurodegeneration, Vol 12, Iss 1, Pp 1-21 (2017)
Publication Year :
2017
Publisher :
BMC, 2017.

Abstract

Abstract Background YKL-40 (also known as Chitinase 3-like 1) is a glycoprotein produced by inflammatory, cancer and stem cells. Its physiological role is not completely understood but YKL-40 is elevated in the brain and cerebrospinal fluid (CSF) in several neurological and neurodegenerative diseases associated with inflammatory processes. Yet the precise characterization of YKL-40 in dementia cases is missing. Methods In the present study, we comparatively analysed YKL-40 levels in the brain and CSF samples from neurodegenerative dementias of different aetiologies characterized by the presence of cortical pathology and disease-specific neuroinflammatory signatures. Results YKL-40 was normally expressed in fibrillar astrocytes in the white matter. Additionally YKL-40 was highly and widely expressed in reactive protoplasmic cortical and perivascular astrocytes, and fibrillar astrocytes in sporadic Creutzfeldt-Jakob disease (sCJD). Elevated YKL-40 levels were also detected in Alzheimer’s disease (AD) but not in dementia with Lewy bodies (DLB). In AD, YKL-40-positive astrocytes were commonly found in clusters, often around β-amyloid plaques, and surrounding vessels with β-amyloid angiopathy; they were also distributed randomly in the cerebral cortex and white matter. YKL-40 overexpression appeared as a pre-clinical event as demonstrated in experimental models of prion diseases and AD pathology. CSF YKL-40 levels were measured in a cohort of 288 individuals, including neurological controls (NC) and patients diagnosed with different types of dementia. Compared to NC, increased YKL-40 levels were detected in sCJD (p 0.05, AUC = 0.71) or in DLB/Parkinson’s disease dementia (PDD) (p > 0.05, AUC = 0.70). Further, two independent patient cohorts were used to validate the increased CSF YKL-40 levels in sCJD. Additionally, increased YKL-40 levels were found in genetic prion diseases associated with the PRNP-D178N (Fatal Familial Insomnia) and PRNP-E200K mutations. Conclusions Our results unequivocally demonstrate that in neurodegenerative dementias, YKL-40 is a disease-specific marker of neuroinflammation showing its highest levels in prion diseases. Therefore, YKL-40 quantification might have a potential for application in the evaluation of therapeutic intervention in dementias with a neuroinflammatory component.

Details

Language :
English
ISSN :
17501326
Volume :
12
Issue :
1
Database :
Directory of Open Access Journals
Journal :
Molecular Neurodegeneration
Publication Type :
Academic Journal
Accession number :
edsdoj.452e7a5af49e1a47d32c0f9339fd5
Document Type :
article
Full Text :
https://doi.org/10.1186/s13024-017-0226-4